Welcome to the e-CCO Library!

P549 A virtual clinic enhances the quality use of anti-TNF dose intensification and rates of treatment success using a treat-to-target approach compared with standard outpatient care in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Srinivasan1,2,3, D.R. van Langenberg1,3, R. Little4, M.P. Sparrow3,4, P. De Cruz2,5, M.G. Ward3,4

Created: Thursday, 30 January 2020, 10:12 AM
P549: Changing Lanes: Switching Therapies in Inflammatory Bowel Disease, An Observational Study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Mc Gettigan, N.(1);Leung, E.(2);Harhen, A.(2);Anderson, E.(2);McMahon, S.(2);Walshe, M.(2);Keohane, J.(2);Sengupta, S.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P549: Effect of maintenance Ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Feagan B.G.*1, Gasink C.2, Pollack P.2, Jacobstein D.2, Gao L.-L.2, Johanns J.2, Miao Y.2, Targan S.3, Ghosh S.4

Created: Wednesday, 20 February 2019, 10:36 AM
P549: One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dalal, R.(1)*;Sharma, P.(2);Bains, K.(3);Pruce, J.(1);Allegretti, J.(1);
Created: Friday, 14 July 2023, 11:05 AM
P549: Oxidative stress and antioxidant capacity biomarkers in adults and children with IBD: current update from OxIBDiet trial
Year: 2022
Source: ECCO'22
Authors: Quattrini, S.(1);Gatti, S.(1);Palpacelli, A.(1);Mattioli, S.(1);Cianfruglia, L.(2);Galezzi, T.(1);Monachesi, C.(1);Quatraccioni, C.(3);Catassi, G.(4);Di Sario, A.(5);Armeni, T.(2);Catassi, C.(1);
Created: Friday, 11 February 2022, 3:56 PM
P549: Systemic cytomegalovirus infection is a relevant factor affecting short- and long-term outcomes of patients with acute severe ulcerative colitis: An 11-year experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

F.S. Macaluso1*, S. Compagnoni1, S. Renna1, S. Maisano1, A. Casà1, G. Solina2, A.G. Rizzo3, F. La Seta4, M. Ventimiglia1, A. Orlando1, M. Cottone1

Created: Thursday, 21 February 2019, 9:14 AM
P549: Vitamin D deficiency as a part of extraintestinal manifestations in IBD Patients: a single-centre experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Georgieva*1, A. Atanassova1, D. Gerova2, M. Todorova2

Created: Friday, 22 February 2019, 9:41 AM
P550 Long-term effectiveness of anti-TNF agents in symptomatic stricturing Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

I. Rodríguez-Lago1, J. Del Hoyo2, M.J. Casanova3, A. Fernández-Clotet4, M.J. García5, R. Ferreiro-Iglesias6, M. Piqueras7, C. Suárez8, A. López-García9, M. Arroyo10, M. Sierra11, P. Delgado-Guillena12, I. Guerra13, O. Merino14, L. Arranz15, J. Llaó16, R. Plaza17, G. Molina18, P. Torres19, P. Pérez-Galindo20, C. Herrera-deGuise21, E. Armesto22, F. Mesonero23, U. Aguirre24, J.P. Gisbert25, EFATECS study group from GETECCU

Created: Thursday, 30 January 2020, 10:12 AM
P550: Anti-mycobacterium paratuberculous therapy in Crohn’s disease: outcomes from tertiary IBD referral centres
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Johnston*1, S. Honap1, B. Al-Hakim1, J. Sanderson1

Created: Friday, 22 February 2019, 9:41 AM
P550: Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Taxonera, C.(1)*;Ha, C.(2);del Pilar Fortes, M.(3);Gardiner, S.(3);Mundayat, R.(3);Ghosh, S.(4);Connor, S.J.(5);
Created: Friday, 14 July 2023, 11:05 AM
P550: Clinical features of demyelination following anti-TNFα therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hendy P.1,2, Heerasing N.*1,2, Walker G.2, Heap G.1,2, Bewshae C.2, Kennedy N.1, Goodhand J.1, Martin R.3, Hobart J.4, Harrower T.5, Coles A.6, Ahmad T.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P550: Early 12-week ultrasound response to treatment, used as a predictor of response at 6 months in Crohn’s disease: A prospective cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Halasz1*, C. Lu1, G. Kaplan1,2, D. Tanyingoh2, C. Seow1, R. Panaccione1, S. Devlin1, S. Wilson3, K. Novak1

Created: Thursday, 21 February 2019, 9:14 AM
P550: Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU
Year: 2022
Source: ECCO'22
Authors: Chaparro, M.(1); G Donday, M.(1);Rubio, S.(2);Nuñez, A.(3);Calviño Suarez, C.(4);Madero, L.(5);Figueira, M.(6);Rivero, M.(7);Pérez Martínez, I.(8);Diz-Lois Palomares, M.T.(9);Huguet, J.M.(10);Marín Pedrosa, S.(11);Aguas, M.(12);Arroyo, M.(13);Ruiz-Cerulla, A.(14);Vázquez Morón, J.M.(15);Fernández-Clotet, A.(16);Guerra, I.(17);López Serrano, P.(18);Rodríguez-Lago, I.(19);Arias García, L.(20);Camargo Camero, R.(21);Casanova, M.J.(1);Martínez Montiel, P.(22);Sendra Rumbeu, P.(23);Suarez Ferrer, C.(24);Valldosera Gomis, G.(25);Armesto, R.(26);Bujanda, L.(27);Calvo Moya, M.(28);Hervías Cruz, D.(29);Robles Alonso, V.(30);de Jorge Turrión, M.Á.(31);Zúñiga de Mora-Figueroa, B.(32);Molina Arriero, G.(33);Acosta, D.(34);Brenes, Y.(34);Hermida, S.(34);Parra, P.(34);Gisbert, J.P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P550: Short term effects of a combined lifestyle intervention in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Lamers, C.R.(1,2);de Roos, N.M.(2);Heerink, H.H.(3);van de Worp - Kalter, L.A.(4);Witteman, B.J.M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P551 Combination therapy in IBD Patients: Do we need to maximise the dose of Azathioprine?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Arieira1,2,3, F. Dias de Castro1,2,3, T. Cúrdia Gonçalves1,2,3, M.J. Moreira1,2,3, J. Cotter1,2,3

Created: Thursday, 30 January 2020, 10:12 AM
P551: 6-Thioguanine nucleotide levels are associated with mucosal healing in patients with Crohn’s disease: A multi-centre, international study
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Mao1, J. Guo1, R. Luber2, B.-l. Chen1, Y. He1, Z.-r. Zeng1, S. Ben-Horin3, M. Sparrow2, R. Xavier4, M.-h. Chen1*

Created: Thursday, 21 February 2019, 9:14 AM
P551: Lack of adherence to infliximab in inflammatory bowel disease patients contributes to loss of response in Crohn’s disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ferreiro Iglesias, R.(1);Gonzalez-Lopez, J.(2);Calvino-Suarez, C.(1);Mauriz-Barreiro, V.(1);Baston-Rey, I.(1);Cruz, R.(3);Dominguez-Munoz, J.E.(1);Barreiro-de Acosta, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P551: Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn's disease: application and prospective validation.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Macedo Silva, V.(1)*;Ferreira, A.I.(1);Lima Capela, T.(1);Arieira, C.(1);Cúrdia Gonçalves, T.(1);Boal Carvalho, P.(1);Dias de Castro, F.(1);Moreira, M.J.(1);Cotter, J.(1);
Created: Friday, 14 July 2023, 11:05 AM
P551: Safety and effectiveness of vedolizumab for the treatment of paediatric patients with Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Fabiszewska, S.(1);Derda, E.(1);Szymańska, E.(1);Osiecki, M.(1);Kierkuś, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P551: Smooth Seton® for perianal fistulas: a knot-less solution
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Stellingwerf M.*1, de Groof J.1, Buskens C.1, Nerkens W.2, Horeman T.2, Bemelman W.1

Created: Wednesday, 20 February 2019, 10:36 AM